JPMorgan lowered the firm’s price target on Omada Health (OMDA) to $26 from $32 and keeps an Overweight rating on the shares. The firm updated the company’s estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health Earnings Call Highlights Profitable Growth
- Omada Health: Profitability Inflection, Double-Digit Growth Outlook, and Undervalued Upside Support Buy Rating
- Omada Health price target lowered to $20 from $25 at Evercore ISI
- Omada Health price target lowered to $18 from $27 at BMO Capital
- Omada Health price target lowered to $30 from $32 at Morgan Stanley